As short-term adjunct in the management of obesity in a medically monitored comprehensive regimen of wt reduction based on exercise, diet & behaviour modification in obese patients w/ body mass index (BMI) of ≥30 kg/m2. Can be initiated in overwt patients w/ BMI of 25-29.9 kg/m2 which increases morbidity risk from a number of disorders.
Should be taken with food: Take at breakfast. Avoid taking near bedtime. Swallow whole, do not chew/crush.
Contraindications
Pulmonary artery HTN; existing heart valve abnormalities or heart murmurs; moderate to severe arterial HTN; cerebrovascular disease; severe cardiac disease including arrhythmias, advanced arteriosclerosis; hypersensitivity to sympathomimetics; hyperthyroidism; agitated states or a history of psychiatric illness including anorexia nervosa & depression; glaucoma; history of drug/alcohol abuse or dependence; concomitant treatment w/ MAOIs or w/in 14 days following MAOI administration. Pregnancy, lactation.
Exclude secondary organic causes of obesity by diagnosis prior to therapy. Not recommended to be co-administered w/ drug products for wt loss. Valvular heart disease, primary pulmonary HTN, mild HTN, diabetes, established CAD, epilepsy, patients receiving psychotrophic drugs or antihypertensives. May impair the ability to drive or operate machinery. Wt loss should be gradual & controlled.
Sympathomimetics. Antagonises adrenergic neurone blockers. Effects potentiated by MAOIs (stop for at least 14 days prior). Concurrent use w/ thyroid hormones may increase CNS stimulation. Alcohol may potentiate CNS side effects.
Manage Account
Change Password
Sign Out
